Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Regimens of therapy

From: The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma

 

Treatment

No. (%)

HAIC regimen

  
 

FOLFOX

20 (69)

 

RALOX

9 (31)

HTP group

  
 

Lenvatinib + Camrelizumab

13(44.8)

 

Lenvatinib + stintilimab

5(17.2)

 

Lenvatinib + tislelizumab

3(10.3)

 

sorafenib + camrelizumab

5(17.2)

 

donafenib + camrelizumab

3(10.3)

TTP group

  
 

Lenvatinib + Camrelizumab

13(65.0)

 

Lenvatinib + stintilimab

1(5.0)

 

Lenvatinib + tislelizumab

1(5.0)

 

sorafenib + camrelizumab

2(10.0)

 

donafenib + camrelizumab

3(15.0)

HAIC treatment cycle

  
 

Median (range)

2(1–6)

TACE treatment cycle

  
 

Median (range)

1(1–3)

  1. HAIC hepatic arterial infusion chemotherapy, FOLFOX HAIC with oxaliplatin, 5-fluorouracil, and leucovorin, RALOX HAIC with raltitrexed plus oxaliplatin, HTP hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TTP transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TACE transarterial chemoembolization
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us